Article

Pharmaceutical Drug Lifecycle: A Comprehensive Scientific Review of Research and Development Phases, Attrition Rates, and Global Disparities

2026-02-12

Abstract excerpt

<h4>Background: </h4> Drug development is one of the most complex, costly, and prolonged processes in biomedical sciences, yet comprehensive reviews integrating quantitative attrition data across all phases with global equity perspectives remain scarce. <h4>Objective:</h4> To provide a comprehensive scientific review of the pharmaceutical drug lifecycle during the Research and Development (R&D) phase, from ini...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 7eca06c9-6b44-53f1-be3f-e592ba7787ad
DOI: 10.20944/preprints202602.0991.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Pharmaceutical Drug Lifecycle: A Comprehensive Scientific Review of Research and Development Phases, Attrition Rates, and Global DisparitiesDOI 10.20944/preprints202602.0991.v1Read

Calendar Period Estimation of Probabilities of Transition in Drug DevelopmentSemantic proximity Read

Non-commercial pharmaceutical R&D: what do neglected diseases suggest about costs and efficiency?Semantic proximity Read

U.S. Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018Semantic proximity Read

Academic challenges on ATMPs’ development: a regulatory perspectiveSemantic proximity Read

A Decade of Innovation: Medicinal Products with New Active Substances Centrally Authorized Within EU Between 2011 and 2020Semantic proximity Read

Global Inequities in Precision Oncology Drug Development: A Cross-Sectional Analysis of FDA Approvals Between 2017-2024Semantic proximity Read

Analysis of recurrent research pathways for assessing and improving effectiveness in life sciences laboratoriesSemantic proximity Read

DRUG REPURPOSING-Overcoming the translational hurdles to clinical use.Semantic proximity Read

Launch Sequencing of Pharmaceuticals with Multiple Therapeutic Indications: Evidence from Seven CountriesSemantic proximity Read

The Alzheimer’s disease drug development landscapeSemantic proximity Read

Lifecycle management of orphan drugs approved in JapanSemantic proximity Read

Development Analysis and Strategic Insights from a 505(b)(2) Reformulation Product: EnzalutamideSemantic proximity Read